p = 0.07), 67% for PTSD (18%, p = 0.02), and 54% for depression (23% change
Highlights include: The race to develop long-acting, oral, and inhalable formulations Insights into AI-driven peptide design and transdermal delivery potential Analytical hurdles in characterizing complex synthetic peptides Perspectives from Novo Nordisk, Waters, Charles River, DFE Pharma, and more A look at novel indicationsfrom cardiovascular protection to alcohol use disorder and cognitive decline Whether youre driving GLP-1 innovation, optimizing delivery platforms, or evaluating market opportunities, this eBook delivers timely intelligence to inform your strategy
Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging
Strengthens skin barrier with ceramides
Your central nervous system relies on glutathione to function properly, and when your supply dips, nerve damage occurs, and disease sets in